159992 创新药
已收盘 06-22 15:00:00
资讯
新帖
简况
再生元制药(REGN)重症肌无力创新药获美欧监管受理 有望成全球首款治疗该症的siRNA药物
金吾财讯 · 06-22 20:32
再生元制药(REGN)重症肌无力创新药获美欧监管受理 有望成全球首款治疗该症的siRNA药物
【券商聚焦】兴业证券维持信达生物(01801)“买入”评级 指其创新药数据优异
金吾财讯 · 06-22 15:08
【券商聚焦】兴业证券维持信达生物(01801)“买入”评级 指其创新药数据优异
全球首个AI创新药三期临床试验将启动，钟南山等医学专家牵头研究
上观新闻 · 06-22 06:01
全球首个AI创新药三期临床试验将启动，钟南山等医学专家牵头研究
中新健康｜创新药企集体拥抱，AI制药竞赛按下加速键
中国新闻网 · 06-21 22:22
中新健康｜创新药企集体拥抱，AI制药竞赛按下加速键
每周股票复盘：一品红（300723）全资子公司创新药获临床试验受理
证券之星 · 06-21 02:30
每周股票复盘：一品红（300723）全资子公司创新药获临床试验受理
博瑞医药称生产经营正常推进 创新药研发管线稳步推进
证券之星 · 06-20 18:32
博瑞医药称生产经营正常推进 创新药研发管线稳步推进
创新药概念震荡反弹，关注创新药ETF易方达（516080）配置价值
证券之星 · 06-18
创新药概念震荡反弹，关注创新药ETF易方达（516080）配置价值
6月18日众生药业（002317）涨停分析：减肥药、MASH创新药、流感药驱动
证券之星 · 06-18
6月18日众生药业（002317）涨停分析：减肥药、MASH创新药、流感药驱动
一品红(300723.SZ)：子公司创新药APH03867片获得临床试验注册申请受理
智通财经 · 06-18
一品红(300723.SZ)：子公司创新药APH03867片获得临床试验注册申请受理
恩华药业：公司一类创新药NH600001的审批进展一切正常顺利
证券之星 · 06-18
恩华药业：公司一类创新药NH600001的审批进展一切正常顺利
创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量
金吾财讯 · 06-18
创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量
港股创新药概念股盘中走高！再鼎医药涨超6%，康方生物涨超5%
老虎资讯综合 · 06-18
港股创新药概念股盘中走高！再鼎医药涨超6%，康方生物涨超5%
博瑞医药二闯港股IPO：创新药烧钱不止，原料药基本盘失守
证券之星 · 06-18
博瑞医药二闯港股IPO：创新药烧钱不止，原料药基本盘失守
热景生物(688068.SH)子公司创新药SGT003注射液临床试验申请获批准
智通财经 · 06-17
热景生物(688068.SH)子公司创新药SGT003注射液临床试验申请获批准
众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 06-17
众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准
智通财经 · 06-17
港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准
恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药
证券之星 · 06-17
恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药
绿叶制药(02186)创新药LY03015(VMAT2抑制剂╱Sigma-1R激动剂)治疗迟发性运动障碍的中国Ⅱ期临床研究取得积极结果
智通财经 · 06-16
绿叶制药(02186)创新药LY03015(VMAT2抑制剂╱Sigma-1R激动剂)治疗迟发性运动障碍的中国Ⅱ期临床研究取得积极结果
海思科：公司负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作
证券之星 · 06-15
海思科：公司负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作
多家药企宣布回购增持计划，能否挽救创新药板块低迷情绪？
澎湃新闻 · 06-15
多家药企宣布回购增持计划，能否挽救创新药板块低迷情绪？
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.743,"timestamp":1782111789000,"preClose":0.737,"halted":0,"volume":1026388804,"delay":0,"changeRate":0.0081,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":0.006,"latestTime":"06-22 15:00:00","open":0.73,"high":0.743,"low":0.712,"amount":745000000,"amplitude":0.0421,"askPrice":0.743,"askSize":43935,"bidPrice":0.742,"bidSize":72259,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782178200000},"marketStatusCode":5,"adr":0,"adjPreClose":0.737,"symbolType":"fund","openAndCloseTimeList":[[1782091800000,1782099000000],[1782104400000,1782111600000]],"highLimit":0.811,"lowLimit":0.663,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.362805,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2645222700","title":"再生元制药(REGN)重症肌无力创新药获美欧监管受理 有望成全球首款治疗该症的siRNA药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2645222700","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645222700?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:32","pubTimestamp":1782131526,"startTime":"0","endTime":"0","summary":"该药用于治疗抗乙酰胆腺受体抗体阳性的成人全身型重症肌无力患者。作为一款针对补体系统C5靶点的小干扰RNA疗法，Cemdisiran若能获批，有望成为全球首款用于治疗gMG的siRNA药物。目前，Cemdisiran仍处于临床研究阶段，其安全性和疗效尚未获得任何国家监管机构的最终批准。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTA0YzE0M2JmNDRmODg4Nzg5OWVhODM3NzhmNzU4MTEwODUxNDg2MTkzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301751","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2468319806.SGD","LU0882574055.USD","LU2106854487.HKD","LU2089984988.USD","LU2362541513.USD","06978","BK1574","LU1917777945.USD","BK4139","LU0109394709.USD","BK1191","LU0114720955.EUR","LU2362540622.SGD","BK4588","BK1161","01477","LU0289739699.SGD","LU0320765992.SGD","LU0889565916.HKD","LU2023250504.SGD","LU2237438978.USD","LU0053666078.USD","LU0823434740.USD","REGN","159992","LU1974910355.USD","LU0823434583.USD","LU2362541273.HKD","LU0823416689.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645041402","title":"【券商聚焦】兴业证券维持信达生物(01801)“买入”评级 指其创新药数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2645041402","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645041402?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:08","pubTimestamp":1782112133,"startTime":"0","endTime":"0","summary":"该结果支持IBI363在一线治疗的进一步探索，第二阶段随机对照研究正在进行中。信达生物将获得首付款6.5亿美元，并有资格获得最高98.5亿美元的研发、监管与商业化里程碑付款，交易总额达105亿美元；对获批上市项目还可获最高达双位数比例的销售分成。公司已有4个跨国药企合作伙伴、5个Co-Co项目及约20个授权合作项目。维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODYzMTA4NTI1Nzg5MjIw.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601377","159992","06978","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645019916","title":"全球首个AI创新药三期临床试验将启动，钟南山等医学专家牵头研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2645019916","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645019916?lang=zh_cn&edition=full","pubTime":"2026-06-22 06:01","pubTimestamp":1782079264,"startTime":"0","endTime":"0","summary":"全球首个由人工智能驱动识别新靶点、设计分子结构的创新药Ⅲ期临床试验将在我国启动。近日，治疗特发性肺纤维化的Rentosertib口服药Ⅲ期临床试验中国研究者会议在北京举行，计划7月启动临床试验，由北京协和医院主任医师徐作军担任牵头研究者，中国工程院院士钟南山、上海市肺科医院院长陈昶担任联合牵头研究者。北京、上海、广州三地名医合作研究，可见这款创新药的“含金量”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223777133630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","AIPO","BK1574","159992","06978","AGIX","CHAT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645018382","title":"中新健康｜创新药企集体拥抱，AI制药竞赛按下加速键","url":"https://stock-news.laohu8.com/highlight/detail?id=2645018382","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645018382?lang=zh_cn&edition=full","pubTime":"2026-06-21 22:22","pubTimestamp":1782051744,"startTime":"0","endTime":"0","summary":"中新网北京6月21日电(记者赵方园)进入2026年，AI制药已经从“要不要做”的选择题，变成一场“谁跑得更快”的新竞赛。近日，和铂医药与百图生科联合宣布，双方将共同创立面向全球市场的新型AI研发公司MegaStreamTechBio。这家新公司将整合百图生科2680亿参数的全模态生命科学大模型xTrimo，同时融合和铂医药在全球全人源抗体领域多年的海量高质量数据资产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606213777099984.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606213777099984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1191","AIPO","BK1574","CHAT","BK1161","ARTY","AGIX","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095063","title":"每周股票复盘：一品红（300723）全资子公司创新药获临床试验受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095063?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:30","pubTimestamp":1781980229,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：全资子公司创新药APH03867片获临床试验注册申请受理公司公告汇总关于全资子公司创新药APH03867片获得临床试验注册申请受理的公告一品红药业集团股份有限公司全资子公司广州一品红制药有限公司自主研发的创新药APH03867片的药物临床试验申请已获国家药品监督管理局受理，适应症为痛风伴高尿酸血症。APH03867片为化学药品1类创新药，通过抑制URAT1活性，促进尿酸排泄，降低血尿酸水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","06978","159992","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644093816","title":"博瑞医药称生产经营正常推进 创新药研发管线稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2644093816","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644093816?lang=zh_cn&edition=full","pubTime":"2026-06-20 18:32","pubTimestamp":1781951549,"startTime":"0","endTime":"0","summary":"博瑞医药近日发布公告称，公司实际控制人袁建栋先生被依法采取取保候审措施。目前公司生产经营运作正常，各项工作有序开展。公司表示，上述事项不涉及上市公司生产经营活动，不会对公司日常经营产生影响。整体来看，博瑞医药正逐步从单一产品布局向平台化代谢疾病研发体系演进。公司表示，将继续围绕代谢疾病等重点领域推进创新药研发及产业化布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://news.stockstar.com/IG2026062000008699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","06978","688166","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644942700","title":"创新药概念震荡反弹，关注创新药ETF易方达（516080）配置价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2644942700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644942700?lang=zh_cn&edition=full","pubTime":"2026-06-18 19:06","pubTimestamp":1781780776,"startTime":"0","endTime":"0","summary":"6月18日，创新药概念震荡反弹，截至收盘，恒生港股通创新药指数上涨1.8%，中证港股通医药卫生综合指数上涨1.8%，中证创新药产业指数上涨2.6%，中证生物科技主题指数上涨1.7%，沪深300医药卫生指数上涨1.0%。中泰证券指出，当前医药板块估值处于历史低位，近期药企密集回购彰显管理层信心，板块底部配置价值进一步强化，尤其看好创新药领域的底部投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026061800035998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["516080","BK1161","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644170386","title":"6月18日众生药业（002317）涨停分析：减肥药、MASH创新药、流感药驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2644170386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644170386?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:41","pubTimestamp":1781768485,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业6月18日涨停收盘，收盘价22.9元。6月18日众生药业涨停的可能因素有：RAY1225减肥药II期临床数据亮眼，亮相ADA大会并完成III期入组；ZSP1601治疗MASH的IIb期顶线数据积极，疗效显著优于安慰剂；昂拉地韦颗粒获CDE优先审评，儿童流感适应症进展顺利；公司2025年扭亏为盈、2026Q1净利润同比增20.83%，创新药管线加速兑现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800022267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0188","06978","BK1574","002317","BK0077","159992","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644523771","title":"一品红(300723.SZ)：子公司创新药APH03867片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644523771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644523771?lang=zh_cn&edition=full","pubTime":"2026-06-18 12:01","pubTimestamp":1781755286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。据悉，APH03867片是公司自主研发的一种新型口服、非肽类小分子URAT1(全称：Urate Transporter 1，中文译为：尿酸转运蛋白1)抑制剂，通过抑制肾脏中URAT1的活性，阻断尿酸在肾小管的重吸收，增加尿酸排泄，达到有效降低血尿酸的效果，可用于改善高尿酸血症和痛风症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159992","06978","300723","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644830771","title":"恩华药业：公司一类创新药NH600001的审批进展一切正常顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2644830771","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644830771?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:54","pubTimestamp":1781754843,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，网传公司创新药发补要拖到明年了，是否属实？谢谢！恩华药业回复：公司一类创新药NH600001的审批进展一切正常顺利！有关公司新药开发的重要信息一切以公司公告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800018446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","LU1064131003.USD","LU1064130708.USD","BK0188","BK1161","159992","BK1574","LU2148510915.USD","BK0070","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"84bb90b0e003ec2bc59dc9b9cb81d467","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","BK4526","ZLAB","LU0140636845.USD","LU0417516571.SGD","01548","LU2045819591.USD","02162","BK1521","LU0516422366.SGD","06978","LU0516423174.USD","LU0348827113.USD","LU0348784397.USD","BK1161","06160","LU2328871848.SGD","HK0000320223.HKD","LU0979878070.USD","LU0326950275.SGD","LU1303224171.USD","02269","LU1794554557.SGD","BK1588","LU2476274308.USD","LU0588546209.SGD","HK0000306701.USD","LU2488822045.USD","BK4531","BK1587","LU2242644610.SGD","BK1589","LU0516423091.SGD","HK0000306685.HKD","LU1720050803.USD","LU0516422952.EUR","LU0456846285.SGD","09688","06855","LU1719994722.HKD","LU0307460666.USD","LU1961090484.USD","IE00BPRC5H50.USD","BK1583","SG9999002463.SGD","LU0561508036.HKD","BK1141","159992","LU1969619763.USD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177778204","title":"港股创新药概念股盘中走高！再鼎医药涨超6%，康方生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177778204","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177778204?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:20","pubTimestamp":1781749207,"startTime":"0","endTime":"0","summary":"6月18日，港股创新药概念股盘中走高，$再鼎医药(ZLAB)$涨超6%，$康方生物(09926)$涨超5%，$亚盛医药(06855)$、$百济神州(06160)$、$药明生物(02269)$、$药明康德(02359)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"84bb90b0e003ec2bc59dc9b9cb81d467","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","VXUS","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0417516902.SGD","LU0348767384.USD","LU0348783233.USD","LU0417516571.SGD","LU2399975544.HKD","LU2476274308.USD","LU0348766576.USD","BK1574","09926","LU0417516738.SGD","ZLAB","LU0348784397.USD","LU0348735423.USD","LU1961090484.USD","LU2488822045.USD","LU0348827113.USD","BK1588","LU0561508036.HKD","BK4588","159992","LU2476274720.SGD","BK4526","LU0348825331.USD","06978","LU0540923850.HKD","LU1794554557.SGD","BK4139","IE00BPRC5H50.USD","BK4585","LU1720050803.USD","09688","BK4531","BK1161","LU0634319403.HKD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644877638","title":"博瑞医药二闯港股IPO：创新药烧钱不止，原料药基本盘失守","url":"https://stock-news.laohu8.com/highlight/detail?id=2644877638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644877638?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:18","pubTimestamp":1781749116,"startTime":"0","endTime":"0","summary":"据招股书披露，博瑞医药现阶段研发重心集中两大方向：全球创新专业的代谢疾病疗法，以及具有竞争力的吸入式药械组合产品系列。博瑞医药在招股书高调宣称其“具备全球同类最佳潜力”。博瑞医药在2025年年报中提到，受流感趋势变化及竞争格局变化影响，奥司他韦原料药及制剂需求及价格产生下滑，使得抗病毒类产品收入、毛利额均大幅减少。2025年，博瑞医药在全球磷酸奥司他韦原料药及中间体市场的市场份额仅为2.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026061800012453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","06978","BK1161","159992","688166","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644714731","title":"热景生物(688068.SH)子公司创新药SGT003注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644714731","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644714731?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:05","pubTimestamp":1781687144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，热景生物 发布公告，近日，公司子公司北京舜景生物医药技术有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，舜景医药研制的创新药SGT003注射液临床试验申请已获得国家药品监督管理局批准。公告显示，SGT003注射液是一款基于舜景医药自主构建的NexTreg技术平台开发的全球首款进入临床研究的新型双特异性抗体候选药物，其核心创新在于精准清除肿瘤微环境调节性T细胞，激活抗肿瘤免疫。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688068","BK1574","BK1161","159992","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644716552","title":"众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644716552","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644716552?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:21","pubTimestamp":1781680867,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问：已经26年6月中旬了，昂拉地韦片25年销量数据还没有公布，需要讳莫如深吗？还是害怕像新冠特效药那样？众生药业回复：您好！昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，销售与流感季节性相关。公司正持续推进学术推广与渠道建设，后续将结合流感周期与医保落地效应，稳步推动昂拉地韦片的商业化工作。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700020366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK1574","BK0188","06978","159992","002317","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644182357","title":"港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644182357","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644182357?lang=zh_cn&edition=full","pubTime":"2026-06-17 13:55","pubTimestamp":1781675740,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，励晶太平洋今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此外，随着江苏万邦医药预计将于2026年下半年启动首次商业销售，届时将再度触发向励晶太平洋支付200万美元。因此，集团预计将于2026年内稳健收取合共700万美元的现金付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159992","IPOS","06978","VXUS","BK4585","BK4588","BK1574","00575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644992317","title":"恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644992317","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644992317?lang=zh_cn&edition=full","pubTime":"2026-06-17 08:52","pubTimestamp":1781657529,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业06月17日在投资者关系平台上答复投资者关心的问题。恩华药业回复：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药，标志着公司从仿制药向自主创新药转型。该药品克服了依托咪酯抑制肾上腺皮质功能的副作用，同时保留了其起效快、苏醒平稳迅速、对呼吸循环影响小的优势。预计该产品获批上市后有望快速扩大销售规模，是公司未来增长的重要引擎之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700007404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0070","002262","BK0239","06978","LU1064131003.USD","159992","LU1064130708.USD","LU2148510915.USD","BK1161","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763638","title":"绿叶制药(02186)创新药LY03015(VMAT2抑制剂╱Sigma-1R激动剂)治疗迟发性运动障碍的中国Ⅱ期临床研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763638","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643763638?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:20","pubTimestamp":1781619613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，集团自主研发的1类创新药LY03015用于治疗迟发性运动障碍的中国Ⅱ期临床试验已完成，取得积极结果，达到主要终点。LY03015为全球首个进入临床的囊泡单胺转运体2和Sigma-1R双靶点创新药，目标适应症为TD和亨廷顿病相关的舞蹈症。集团通过自主建立的AI药物设计平台，设计了全新结构的小分子药物LY03015，不仅解决了上述安全性风险，而且高活性靶向VMAT2和Sigma-1R，发挥“症状控制”和“病理改善”的双重作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186","BK1583","BK1191","BK1161","159992","BK1574","06978","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753762","title":"海思科：公司负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753762","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753762?lang=zh_cn&edition=full","pubTime":"2026-06-15 15:51","pubTimestamp":1781509872,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科(002653)06月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，海思科买礼来的品种，如何进行定价？是否需要履行评估手续？海思科回复：您好，根据公司与礼来的合作协议，公司将负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作，并非公司从礼来购买品种，不涉及定价和评估，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500015564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","06978","BK0239","BK0033","BK1574","BK1161","159992","BK0188","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227978","title":"多家药企宣布回购增持计划，能否挽救创新药板块低迷情绪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227978","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643227978?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:03","pubTimestamp":1781503380,"startTime":"0","endTime":"0","summary":"在国内生物医药板块持续走低的背景下，多家国内创新药企宣布了回购或增持计划，向市场传递信心。 6月15日早盘，港股龙头药企中国生物制药公告称，公司董事会决议通过一项股份购买计划，将视市场情况于未来12个月以不超过20亿港元总价在公开市场上回购本公司股份，及指示负责管理股份奖励计划的受托人购买股份。据不完全统计，这是今年以来创新药企业最大金额的回购计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-15/doc-inicnisv8303280.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-15/doc-inicnisv8303280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782154689980,"stockEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":-0.0487},{"period":"3month","weight":-0.0425},{"period":"6month","weight":-0.129},{"period":"1year","weight":-0.0413},{"period":"ytd","weight":-0.1059}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0726},{"period":"6month","weight":0.0564},{"period":"1year","weight":0.2391},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}